A bispecific antibody joined first-line lymphoma chemo. Complete response hit 95%.

Diffuse large B-cell lymphoma is the most common aggressive lymphoma, and for decades the opening move has been the same chemotherapy backbone. A newer version swaps one drug in — polatuzumab vedotin replacing vincristine — to make pola-R-CHP. The question in this trial is what happens when a second, very different kind of drug is added on top.

Blood published on October 6 a phase 2 study that folded glofitamab, a bispecific antibody, into that first-line regimen for people with newly diagnosed disease [s1].

What glofitamab does

Standard chemoimmunotherapy relies on rituximab to flag cancerous B cells for destruction. Glofitamab works differently: the trial describes it as a CD3xCD20 bispecific antibody, meaning one end grabs the CD20 marker on a lymphoma cell and the other grabs CD3 on a T cell, physically pulling the patient's own immune cells against the tumour [s1].

That mechanism is already used in relapsed disease. Moving it into first-line treatment, alongside full chemotherapy, is the step this study tests — and the obvious worry is whether stacking an immune-engaging antibody onto chemotherapy adds toxicity faster than it adds benefit.

The trial

The study enrolled patients with newly diagnosed DLBCL and an International Prognostic Index of 2 or higher — that is, a higher-risk group by the standard scoring tool [s1]. A total of 41 patients enrolled [s1].

The median age was 61 years, with a range of 35 to 86, and 59% were male [s1]. IPI scores were 2 in 39%, 3 in 41%, and 4 in 20%, and 86% of patients had stage III or IV disease [s1]. Most had DLBCL, not otherwise specified (78%), and 12% had high-grade B-cell lymphoma with translocations in MYC and BCL-2 and/or BCL-6 — the so-called double-hit tumours that tend to do worse [s1].

The schedule was deliberately staggered. Patients received two cycles of pola-R-CHP first, with one cycle of the older R-CHOP permitted; glofitamab was added during cycles 3 through 6 and then used on its own for cycles 7 and 8 [s1]. Delaying the bispecific antibody until the third cycle is the design choice the investigators lean on to explain the safety results below.

The primary objective was the best complete response rate — the share of patients whose cancer became undetectable on imaging at any point [s1].

The result

The best complete response rate was 95%, or 39 of 41 patients, with a 95% confidence interval of 83 to 99 [s1]. Both of the patients who had only a partial response at the end of therapy later converted to a complete response without any further intervention [s1].

Durability, so far, looks consistent with that. With a median follow-up of 23.9 months, the median progression-free survival had not been reached — meaning more than half the patients had not relapsed by the time of analysis — and the estimated 24-month progression-free survival was 95% (95% CI, 89 to 100) [s1].

The safety signal

The staggered schedule appears to have paid off on the specific toxicities that make immune-engaging antibodies hard to combine with chemotherapy.

Cytokine release syndrome — the inflammatory reaction that can follow T-cell-engaging therapy — occurred in four patients, 10%, and every case was grade 1, the mildest category [s1]. No immune effector cell-associated neurotoxicity syndrome, the neurological complication known as ICANS, was reported at all [s1].

The investigators attribute the low rates to the delayed incorporation of glofitamab, giving the chemotherapy time to reduce the tumour burden before the bispecific antibody is introduced [s1].

The caveats that matter

It is single-arm. There is no comparison group receiving pola-R-CHP without glofitamab, so the trial cannot say how much of the 95% complete-response rate is attributable to the added antibody rather than to the backbone it was built on. Pola-R-CHP alone already produces high response rates.

It is small. Forty-one patients is enough to generate a striking number and a confidence interval, but not enough to characterise rarer harms or to be confident the response rate would hold in a larger, more varied population.

The follow-up is still short for this disease. At a median of 23.9 months, a 24-month progression-free estimate of 95% is encouraging, but DLBCL relapses can occur later, and progression-free survival is not the same as cure or overall survival.

Enrolment favoured one centre's selection. As a phase 2 study, it was designed to decide whether the regimen is worth testing further, not to change practice on its own.

What to watch

The investigators frame the result as supporting further evaluation of the regimen [s1]. The meaningful next step is a randomised comparison against pola-R-CHP alone, powered to show whether adding glofitamab improves outcomes that patients feel — relapse and survival — rather than a response rate measured on a scan. The trial is registered on ClinicalTrials.gov as NCT05800366 [s2].

This article describes early-phase trial results, including a treatment schedule and adverse events, for informational purposes only. It is not medical advice and not a recommendation about any therapy.

Sources

• [s1] A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma. Blood, published online 2026-10-06.
• [s2] A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma. ClinicalTrials.gov identifier NCT05800366.